HDV News & Analysis
3 articles
Market Mood
4.8% Yield Portfolio for $1.1M Remains Stable Amid Market Changes
A diversified portfolio of $1.1 million targets a yield of 4.8%, providing an annual income of $52,800 for a 72-year-old retiree. The portfolio includes HDV, MUB, O, SPYI, and SGOV, with a 5% liquidity sleeve in SGOV to hedge against market downturns. Since 2020, Realty Income's dividend increased from $0.2325 to $0.2705, showcasing effective income generation. The 10-year Treasury yield is near 4.5%, with the Fed Funds upper bound at 3.75%, allowing this portfolio to earn a real premium over risk-free alternatives.
Read More
VIG vs HDV: Comparing Dividend Yields of 1.7% and 3%
The Vanguard Dividend Appreciation ETF (VIG) offers a yield of 1.7% and requires companies to have 10 consecutive years of dividend growth, while the iShares Core High Dividend ETF (HDV) yields 3% and holds 75 stocks. VIG has outperformed HDV on a 10-year annualized basis, delivering 12.9% compared to HDV's 9.4%. Additionally, VIG contains 334 stocks, resulting in a 21% overlap with HDV, making them complementary. Choosing between these ETFs depends on investor preferences for dividend growth versus immediate income generation.
Read More
Vir Biotechnology (VIR) Trading at $11.09 and P/E Ratio of 5.92
Vir Biotechnology, Inc. (VIR) shares were trading at $11.09 as of April 20th, with a trailing P/E ratio of 5.92. The company is focusing on Chronic Hepatitis Delta (HDV) and its oncology platform, with Phase 2 data indicating a 77% Target Not Detected (TND) rate. Regulatory uncertainties could affect their 2027 BLA timeline. Financially, VIR holds $781 million in cash, providing a runway into late 2027, although dilution risks exist ahead of key data releases in Q1 2027, which could significantly impact valuation.
Read More